US scientists have developed an oral method of administering insulin that can be a less painful alternative to millions of people worldwide with diabetes who have to inject themselves with the drug to manage their blood-sugar levels.
The team has successfully encapsulated insulin using Cholestosomes -- a neutral, lipid-based particle -- that can be administered orally with tiny vesicles that can deliver insulin where it needs to go without injecting.
The biggest obstacle to delivering insulin orally is ushering it through the stomach intact. Proteins such as insulin are no match for the harsh, highly acidic environment of the stomach. They degrade before they get a chance to move into the intestines and then the bloodstream where they're needed, the study said.
However, the new vesicles that are made of naturally occurring lipid molecules are normal building blocks of fats, the researchers said, adding that they are unlike other lipid-based drug carriers, called liposomes.
"Most liposomes need to be packaged in a polymer coating for protection. Here, we are just using simple lipid esters to make vesicles with the drug molecules inside," said lead researcher Mary McCourt, Professor at Niagara University in New York, US.
Computer modelling showed that once the lipids are assembled into spheres, they form neutral particles resistant to attack from stomach acids.
Drugs can be loaded inside, and the tiny packages can pass through the stomach without degrading.
When cholestosomes reach the intestines, the body recognises them as something to be absorbed. The vesicles pass through the intestines, into the bloodstream, and then cells take them in and break them apart, releasing insulin.
Studies with rats showed that certain formulations of cholestosomes loaded with insulin have high bioavailability, which means the vesicles travel into the bloodstream where the insulin needs to be, the researchers concluded.
The results were presented at the 252nd National Meeting and Exposition of the American Chemical Society (ACS), in Philadelphia, recently.
--IANS
rt/in/dg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
